A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder

Karen Wagner, Ray Berard, Murray B. Stein, Erica Wetherhold, David J. Carpenter, Phillip Perera, Michelle Gee, Katherine Davy, Andrea Machin

Research output: Contribution to journalArticle

167 Citations (Scopus)

Abstract

Background: Social anxiety disorder is a debilitating, highly prevalent disorder in children and adolescents. If left untreated, it can interfere with emotional, social, and school functioning. Objective: To evaluate the efficacy and tolerability of paroxetine in children and adolescents with social anxiety disorder. Design and Setting: Multicenter, 16-week, randomized, double-blind, placebo-controlled, flexible-dose, parallel-group, outpatient study. Patients: A total of 322 children (8-11 years of age) and adolescents (12-17 years of age) with social anxiety disorder as their predominant psychiatric illness. Intervention: Eligible patients were randomized (1:1) to receive paroxetine (10-50 mg/d) or placebo. Results: Four hundred twenty-five patients were screened, and 322 were randomized to treatment. Of these, 319 were included in the intention-to-treat population (paroxetine, n = 163; placebo, n = 156). At the week 16 last observation carried forward end point, the odds of responding (Clinical Global Impression-Improvement score of 1 or 2) were statistically significantly greater for paroxetine (77.6% response [125/161]) than for placebo (38.3% response [59/154]) (adjusted odds ratio, 7.02; 95% confidence interval, 4.07 to 12.11; P<.001). The proportion of patients who were "very much" improved (Clinical Global Impression-Improvement score of 1) was 47.8% (77/161) for paroxetine compared with 14.9% (23/ 154) for placebo. Adverse events occurring at an incidence of 5% or greater for paroxetine and twice that for placebo were insomnia (14.1% vs 5.8%), decreased appetite (8.0% vs 3.2%), and vomiting (6.7% vs 1.9%). Withdrawals due to adverse events were infrequent (5.5% [9/163] for paroxetine and 1.3% [2/156] for placebo). Conclusion: Paroxetine is an effective, generally well-tolerated treatment for pediatric social anxiety disorder.

Original languageEnglish (US)
Pages (from-to)1153-1162
Number of pages10
JournalArchives of General Psychiatry
Volume61
Issue number11
DOIs
StatePublished - Nov 2004

Fingerprint

Paroxetine
Placebos
Social Phobia
Sleep Initiation and Maintenance Disorders
Appetite
Vomiting
Psychiatry
Outpatients
Odds Ratio
Observation
Confidence Intervals
Pediatrics
Incidence
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. / Wagner, Karen; Berard, Ray; Stein, Murray B.; Wetherhold, Erica; Carpenter, David J.; Perera, Phillip; Gee, Michelle; Davy, Katherine; Machin, Andrea.

In: Archives of General Psychiatry, Vol. 61, No. 11, 11.2004, p. 1153-1162.

Research output: Contribution to journalArticle

Wagner, Karen ; Berard, Ray ; Stein, Murray B. ; Wetherhold, Erica ; Carpenter, David J. ; Perera, Phillip ; Gee, Michelle ; Davy, Katherine ; Machin, Andrea. / A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. In: Archives of General Psychiatry. 2004 ; Vol. 61, No. 11. pp. 1153-1162.
@article{73f5e37a39084e1eabe51660720ef6f8,
title = "A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder",
abstract = "Background: Social anxiety disorder is a debilitating, highly prevalent disorder in children and adolescents. If left untreated, it can interfere with emotional, social, and school functioning. Objective: To evaluate the efficacy and tolerability of paroxetine in children and adolescents with social anxiety disorder. Design and Setting: Multicenter, 16-week, randomized, double-blind, placebo-controlled, flexible-dose, parallel-group, outpatient study. Patients: A total of 322 children (8-11 years of age) and adolescents (12-17 years of age) with social anxiety disorder as their predominant psychiatric illness. Intervention: Eligible patients were randomized (1:1) to receive paroxetine (10-50 mg/d) or placebo. Results: Four hundred twenty-five patients were screened, and 322 were randomized to treatment. Of these, 319 were included in the intention-to-treat population (paroxetine, n = 163; placebo, n = 156). At the week 16 last observation carried forward end point, the odds of responding (Clinical Global Impression-Improvement score of 1 or 2) were statistically significantly greater for paroxetine (77.6{\%} response [125/161]) than for placebo (38.3{\%} response [59/154]) (adjusted odds ratio, 7.02; 95{\%} confidence interval, 4.07 to 12.11; P<.001). The proportion of patients who were {"}very much{"} improved (Clinical Global Impression-Improvement score of 1) was 47.8{\%} (77/161) for paroxetine compared with 14.9{\%} (23/ 154) for placebo. Adverse events occurring at an incidence of 5{\%} or greater for paroxetine and twice that for placebo were insomnia (14.1{\%} vs 5.8{\%}), decreased appetite (8.0{\%} vs 3.2{\%}), and vomiting (6.7{\%} vs 1.9{\%}). Withdrawals due to adverse events were infrequent (5.5{\%} [9/163] for paroxetine and 1.3{\%} [2/156] for placebo). Conclusion: Paroxetine is an effective, generally well-tolerated treatment for pediatric social anxiety disorder.",
author = "Karen Wagner and Ray Berard and Stein, {Murray B.} and Erica Wetherhold and Carpenter, {David J.} and Phillip Perera and Michelle Gee and Katherine Davy and Andrea Machin",
year = "2004",
month = "11",
doi = "10.1001/archpsyc.61.11.1153",
language = "English (US)",
volume = "61",
pages = "1153--1162",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder

AU - Wagner, Karen

AU - Berard, Ray

AU - Stein, Murray B.

AU - Wetherhold, Erica

AU - Carpenter, David J.

AU - Perera, Phillip

AU - Gee, Michelle

AU - Davy, Katherine

AU - Machin, Andrea

PY - 2004/11

Y1 - 2004/11

N2 - Background: Social anxiety disorder is a debilitating, highly prevalent disorder in children and adolescents. If left untreated, it can interfere with emotional, social, and school functioning. Objective: To evaluate the efficacy and tolerability of paroxetine in children and adolescents with social anxiety disorder. Design and Setting: Multicenter, 16-week, randomized, double-blind, placebo-controlled, flexible-dose, parallel-group, outpatient study. Patients: A total of 322 children (8-11 years of age) and adolescents (12-17 years of age) with social anxiety disorder as their predominant psychiatric illness. Intervention: Eligible patients were randomized (1:1) to receive paroxetine (10-50 mg/d) or placebo. Results: Four hundred twenty-five patients were screened, and 322 were randomized to treatment. Of these, 319 were included in the intention-to-treat population (paroxetine, n = 163; placebo, n = 156). At the week 16 last observation carried forward end point, the odds of responding (Clinical Global Impression-Improvement score of 1 or 2) were statistically significantly greater for paroxetine (77.6% response [125/161]) than for placebo (38.3% response [59/154]) (adjusted odds ratio, 7.02; 95% confidence interval, 4.07 to 12.11; P<.001). The proportion of patients who were "very much" improved (Clinical Global Impression-Improvement score of 1) was 47.8% (77/161) for paroxetine compared with 14.9% (23/ 154) for placebo. Adverse events occurring at an incidence of 5% or greater for paroxetine and twice that for placebo were insomnia (14.1% vs 5.8%), decreased appetite (8.0% vs 3.2%), and vomiting (6.7% vs 1.9%). Withdrawals due to adverse events were infrequent (5.5% [9/163] for paroxetine and 1.3% [2/156] for placebo). Conclusion: Paroxetine is an effective, generally well-tolerated treatment for pediatric social anxiety disorder.

AB - Background: Social anxiety disorder is a debilitating, highly prevalent disorder in children and adolescents. If left untreated, it can interfere with emotional, social, and school functioning. Objective: To evaluate the efficacy and tolerability of paroxetine in children and adolescents with social anxiety disorder. Design and Setting: Multicenter, 16-week, randomized, double-blind, placebo-controlled, flexible-dose, parallel-group, outpatient study. Patients: A total of 322 children (8-11 years of age) and adolescents (12-17 years of age) with social anxiety disorder as their predominant psychiatric illness. Intervention: Eligible patients were randomized (1:1) to receive paroxetine (10-50 mg/d) or placebo. Results: Four hundred twenty-five patients were screened, and 322 were randomized to treatment. Of these, 319 were included in the intention-to-treat population (paroxetine, n = 163; placebo, n = 156). At the week 16 last observation carried forward end point, the odds of responding (Clinical Global Impression-Improvement score of 1 or 2) were statistically significantly greater for paroxetine (77.6% response [125/161]) than for placebo (38.3% response [59/154]) (adjusted odds ratio, 7.02; 95% confidence interval, 4.07 to 12.11; P<.001). The proportion of patients who were "very much" improved (Clinical Global Impression-Improvement score of 1) was 47.8% (77/161) for paroxetine compared with 14.9% (23/ 154) for placebo. Adverse events occurring at an incidence of 5% or greater for paroxetine and twice that for placebo were insomnia (14.1% vs 5.8%), decreased appetite (8.0% vs 3.2%), and vomiting (6.7% vs 1.9%). Withdrawals due to adverse events were infrequent (5.5% [9/163] for paroxetine and 1.3% [2/156] for placebo). Conclusion: Paroxetine is an effective, generally well-tolerated treatment for pediatric social anxiety disorder.

UR - http://www.scopus.com/inward/record.url?scp=7744238183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7744238183&partnerID=8YFLogxK

U2 - 10.1001/archpsyc.61.11.1153

DO - 10.1001/archpsyc.61.11.1153

M3 - Article

C2 - 15520363

AN - SCOPUS:7744238183

VL - 61

SP - 1153

EP - 1162

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 11

ER -